Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Melphalan-induced serpentine supravenous hyperpigmentation with associated venous thrombosis.

Created on 23 Aug 2026

Authors

Sofia Gueroum, Bouchra Baghad, Fatima Zahra Benhayoun, Hanane Rachadi, Soumiya Chiheb

Published in

Oxford medical case reports. Volume 2026. Issue 8. Pages omag158. Epub Aug 22, 2026.

Abstract

Serpentine supravenous hyperpigmentation (SSH) is a rare cutaneous adverse reaction characterized by linear hyperpigmentation along superficial veins following intravenous drug administration, most commonly chemotherapy. We report a rare case of melphalan-induced SSH complicated by superficial venous thrombosis. A 54-year-old man treated for kappa light-chain multiple myeloma developed asymptomatic serpiginous hyperpigmented lesions along the superficial venous network one day after peripheral intravenous melphalan infusion prior to autologous stem cell transplantation. Ten days later, the lesions became painful, and Doppler ultrasound revealed thrombosis of the involved superficial veins. The patient was successfully treated with oral anticoagulation and local care. SSH is generally considered benign and self-limited; however, painful lesions should prompt evaluation for vascular complications such as thrombosis. This case expands the spectrum of chemotherapeutic agents associated with SSH and highlights the importance of early recognition of atypical presentations and complications.

PMID:
42633082
Bibliographic data and abstract were imported from PubMed on 23 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement